Abstract
Objectives While the use of novel oral anticoagulants (NOACs) has been approved in the treatment of non-valvular atrial fibrillation (NVAF), we are lacking studies on individual NOACs in NVAF with valvular heart disease (VHD) including bio-prosthetic valve and valve repair. We aimed to determine the efficacy and safety of rivaroxaban compared to warfarin in prevention of thromboembolism in patients with NVAF with VHD.
Methods We searched PubMed, MEDLINE, and EMBASE including only RCTs and Cohort studies from inception till April 2021. Eligible studies compared rivaroxaban with warfarin in patients with NVAF with VHD. We excluded patients with valvular AF. We used Review Manager (version 5.4, Cochrane Collaboration, Oxford, UK) applying the Mantel-Haenszel test and followed PRISMA guidelines. Risk ratio (RR) and 95% confidence intervals (CIs) were estimated using a random-effects method and heterogeneity using I squared test.
Results We had total of 23136 participants in both groups. Our results showed stroke and systemic thromboembolism in 88 of 4258 (2.06%) patients in the rivaroxaban group compared to 351 of 18878 (1.85%) patients in the warfarin group (RR 0.76; 95% CI, 0.55, 1.06; heterogeneity I2 = 35%, P = 0.10), major bleeding in 247 of 4258 (5.8%) patients in the rivaroxaban group compared to 270 of 18879 (1.4%) patients in the warfarin group (HR 1.68; 95% CI, 0.59, 4.77; heterogeneity I2 = 97%) and intracranial hemorrhage in 24 out of 2583 (0.9%) patients in the rivaroxaban group compared to 35 of 2160 (1.6%) in warfarin group (HR 0.49; 95% CI, 0.16, 1.56; heterogeneity I2 = 70%).
Conclusions Our results show that rivaroxaban is comparable to warfarin in prevention of stroke and systemic thromboembolism in patients with NVAF with VHD. Rivaroxaban is also comparable to warfarin in bleeding risks in these patients.
REGISTRATION NUMBER CRD42021222490
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
REGISTRATION NUMBER in PROSPERO: CRD42021222490
Clinical Protocols
https://www.crd.york.ac.uk/PROSPERO/
Funding Statement
No any funding was received for this paper.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The paper is exempt from IRB due to secondary data analysis from published articles.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email: Nischit.baral{at}mclaren.org
Email: anjan.katel3{at}gmail.com
Email: Govinda.adhikari{at}mclaren.org
Email: Mahin.khan{at}mclaren.org
Email: Hafiz.khan{at}mclaren.org
Email: rohit.rauniyar{at}mclaren.org
Email: Maxwell.akanbi{at}mclaren.org
Email: Bilal.malik{at}mclaren.org
Muhammad.ahmad{at}mclaren.org
Email: ashiya.khan{at}mclaren.org
Email: Basel.abdelazeem{at}mclaren.org
Email: Pramodkumar.savarapu{at}gmail.com
Email: shakirullahisa{at}yahoo.com
arvindkunadi{at}yahoo.com
Email: Parul.sud{at}mclaren.org
Email: Hameem.Changezi{at}mclaren.org
Funding: None
Disclosure: All authors have no conflict of interest to disclose
Data Availability
The data are provided from all the individuals studies referenced in the journal.